The research indicated that NSCLC patients with positive PD-L1 expression but without EGFR mutations achieved better progression-free survival (PFS) and overall survival (OS) with pembrolizumab in comparison to chemotherapy [14]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.